ArticleAmerican journal of clinical pathology2015
Extensive survey of STAT6 expression in a large series of mesenchymal tumors.
Article in American journal of clinical pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 203 citations in OpenAlex.
- Article
- Primary orbital solitary fibrous tumor with an 18-year course of five recurrences and extensive sinonasal metastasis following eyeball enucleation: a case report.Frontiers in medicine · 2026Article
- Smooth muscle actin (SMA)-negative uninodular plexiform fibromyxoma: case report of a challenging atypical presentation of a rare gastric mesenchymal tumor in a 25-year-old female.AME case reports · 2026Article
- Complete Resection of a Giant Hypervascular Pelvic Floor Solitary Fibrous Tumor Using Intraoperative Balloon Occlusion and Staged Open Abdomen Management: A Case Report.Surgical case reports · 2026Article
- Solitary fibrous tumor: an updated review.Journal of pathology and translational medicine · 2026Article
- Solitary fibrous tumor of kidney and renal hilus: a multi-institutional clinicopathologic analysis of 43 cases.Virchows Archiv : an international journal of pathology · 2025Article
- Article
- Case Report: Retroperitoneal dedifferentiated solitary fibrous tumor with unexpected Pax-2 expression, mimicking high grade clear cell renal cell carcinoma.Frontiers in oncology · 2025Article
- Advances in the molecular biology of the solitary fibrous tumor and potential impact on clinical applications.Cancer metastasis reviews · 2024Review
- Epithelioid solitary fibrous tumors from CNS and soft tissues: an unusual morphologic variant.Diagnostic pathology · 2024Article
- Clinical outcomes of patients undergoing reoperation with solitary fibrous tumors/hemangiopericytomas and malignant progression of tumors.Neurosurgical review · 2024Article
- A Comprehensive Clinicopathologic and Molecular Reappraisal of GLI1 -altered Mesenchymal Tumors with Pooled Outcome Analysis Showing Poor Survival in GLI1 - amplified Versus GLI1- rearranged Tumors.The American journal of surgical pathology · 2024Article
- Different Shades of Desmoid-Type Fibromatosis (DTF): Detection of Noval Mutations in the Clinicopathologic Analysis of 32 Cases.Diagnostics (Basel, Switzerland) · 2024Article
- Malignant solitary fibrous tumor of the kidney with IGF2 secretion and without hypoglycemia.World journal of surgical oncology · 2024Article
- Solitary fibrous tumor occurring in the colon as submucosal mesenchymal lesion: report of two cases and review of the literature.Clinical journal of gastroenterology · 2024Review
- Functional Classification of Fusion Proteins in Sarcoma.Cancers · 2024Review
- Rarest of the Rare - Malignant Solitary Fibrous Tumour of the Breast: Case Report and Literature Review.Maedica · 2024Article
- Exploring Solitary Fibrous Tumors at a Tertiary Cancer Center: Clinicopathological and Immunomorphologic Profile.Cureus · 2024Article
- Giant cell-rich solitary fibrous tumour of the urinary bladder: case report of an unusual histological variant and literature review.Diagnostic pathology · 2024Review
- Comprehensive analysis reveals potential therapeutic targets and an integrated risk stratification model for solitary fibrous tumors.Nature communications · 2023Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesExpression of strong nuclear STAT6 is thought to be a specific marker for solitary fibrous tumors (SFTs). Little is known about subtle expression patterns in other mesenchymal lesions.
methodsWe performed immunohistochemical studies against the C-terminus of STAT6 in tissue microarrays and whole sections, comprising 2366 mesenchymal lesions.
resultsStrong nuclear STAT6 was expressed in 285 of 2,021 tumors, including 206 of 240 SFTs, 49 of 408 well-differentiated/dedifferentiated liposarcomas, eight of 65 unclassified sarcomas, and 14 of 184 desmoid tumors, among others. Expression in SFTs was predominately limited to the nucleus. Other positive tumors typically expressed both nuclear and cytoplasmic STAT6. Complete absence of STAT6 was most common in pleomorphic liposarcoma and alveolar soft part sarcoma (60% and 72% cases negative, respectively).
conclusionsStrong nuclear STAT6 is largely specific for SFTs. Physiologic low-level cytoplasmic/nuclear expression is common in mesenchymal neoplasia and is of uncertain significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.